Royal Bank of Canada’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Royal Bank of Canada’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27	Closed	–	–	7805
2024 Q1	$0	Hold	27	–	–	﹤0.01%	7884
2023 Q4	$0	Hold	27	–	–	﹤0.01%	7906
2023 Q3	$0	Hold	27	–	–	﹤0.01%	7970
2023 Q2	$0	Buy	+27	New	+$277	﹤0.01%	7936
2022 Q4	–	Sell	-5	Closed	–	–	8028
2022 Q3	$0	Buy	+5	New	+$348	﹤0.01%	8106
2022 Q2	–	Sell	-16	Closed	-$2K	–	7973
2022 Q1	$2K	Sell	16 -39	-71%	-$9K	﹤0.01%	7535
2021 Q4	$16K	Buy	55 +29	+112%	+$11.1K	﹤0.01%	6898
2021 Q3	$10K	Buy	26 +9	+53%	+$3.84K	﹤0.01%	6977
2021 Q2	$7K	Buy	+17	New	+$7.36K	﹤0.01%	7003

Other funds holding FNCH

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Royal Bank of Canada's FNCH Position: Q2 2024 in Review

Royal Bank of Canada sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 27 shares.

Royal Bank of Canada first reported a position in FNCH in Q2 2021 and held it in 9 quarters. The position peaked at $16K in Q4 2021. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

Royal Bank of Canada reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Royal Bank of Canada sold 27 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024.
Royal Bank of Canada first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
Royal Bank of Canada's Finch Therapeutics Group, Inc. Common Stock position peaked at $16K in Q4 2021.
1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.